Drug Approval | August 03, 2021
AYUSH 64 effective in mild and moderate COVID 19
It works as an adjunct to standard care based on robust clinical trials
It works as an adjunct to standard care based on robust clinical trials
This deal makes Meddo, one of the largest health-tech players in India
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Price band in the range of Rs 933 to Rs 954
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Subscribe To Our Newsletter & Stay Updated
